AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03798119
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
Trial: NCT00692354
Drug: CHR-2797 (tosedostat)
RxNorm normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
Trial: NCT00272714
Drug: Afimoxifene (0.057%) in hydroalcoholic gel
RxNorm normalized name: Afimoxifene
DrugBank: Afimoxifene (DB04468)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03945539
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
Trial: NCT00991146
Drug: canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: canakinumab
Trial: NCT03279289
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg administered intravenous infusion on day 1
Trial: NCT03279289
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 intravenous infusion
Trial: NCT03279289
Drug: folinic acid (dl racemic)
RxNorm normalized name: oxolinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous infusion
Trial: NCT03279289
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours
Trial: NCT00646282
Drug: doxercalciferol
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
Trial: NCT01444807
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib 400 mg bid
Trial: NCT00668356
Drug: didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
Trial: NCT00668356
Drug: didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
Trial: NCT01964391
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
Trial: NCT01964391
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
Trial: NCT03104816
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01964391
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
Trial: NCT01964391
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
Trial: NCT02504463
Drug: Samidorphan IV
DrugBank: Samidorphan (DB12543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV administration
Trial: NCT02504463
Drug: [14c]-Samidorphan sublingual
DrugBank: Samidorphan (DB12543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single sublingual administration containing radiolabel
Trial: NCT02504463
Drug: [14c]-Samidorphan oral
DrugBank: Samidorphan (DB12543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral administration containing radiolabel
Trial: NCT00825669
Drug: TACE
RxNorm normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
Trial: NCT01021696
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol Max. dose: 3g/d
Trial: NCT01021696
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
Trial: NCT01021696
Drug: Buprenorphine plaster
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5ųg/h, change each 7.day; max. dose: 10ųg/h
Trial: NCT01021696
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25mgx1/d; max 300mg/d
Trial: NCT01331421
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT00156936
Drug: Medisorb naltrexone 380 mg
RxNorm normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
Trial: NCT00156936
Drug: Oral naltrexone to Medisorb naltrexone 380 mg
RxNorm normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
Trial: NCT02689986
Drug: Bendamustine, Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bendamustine, Rituximab
Trial: NCT01143389
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
Trial: NCT00720447
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00720447
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00720447
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00720447
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02294942
Drug: RANCAD
RxNorm normalized name: rancid beef preparation
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-Release RANCAD
Trial: NCT02876250
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
Trial: NCT03626298
Drug: Adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
Trial: NCT00791076
Drug: Pancreatic Polypeptide (PP)
RxNorm normalized name: Heme iron polypeptide
DrugBank: Pancreatic Polypeptide (DB12822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2pmol/kg-1/min-1 PP infused continuously over 72 hours.
Trial: NCT02718599
Drug: terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
Trial: NCT02125305
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03985293
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg tablet once daily
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablet once daily
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg once daily (with 250mg tablets)
Trial: NCT03790020
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg tablet once daily
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg once daily (with 250mg tablets)
Trial: NCT01106469
Drug: JNJ-41443532
RxNorm normalized name: JNJ-41443532
DrugBank: JNJ-41443532 (DB12632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg once daily (with 250mg tablets)
Trial: NCT02183701
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02565134
Drug: PAC-14028 cream 0.1%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02565134
Drug: PAC-14028 cream 0.3%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02565134
Drug: PAC-14028 cream 1.0%
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT02565134
Drug: PAC-14028 cream vehicle
RxNorm normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT03889197
Drug: Sodium supplementation guided by urine sodium concentration algorithm
RxNorm normalized name: Urin DS
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
Trial: NCT02361476
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection - during surgery
Trial: NCT01857596
Drug: bupropion, Lorexys low-dose, Lorexys moderate-dose
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorexys is a proprietary fixed-dose combination of two agents
Trial: NCT00814333
Drug: Thrombin-JMI
RxNorm normalized name: Thrombin-JMI
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU, to nasal mucosa via syringe spray applicator
Trial: NCT00830869
Drug: IXAZOMIB
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Trial: NCT00877773
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
Trial: NCT03896503
Drug: Berzosertib
RxNorm normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03896503
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00711165
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mcg, qd for 8 weeks
Trial: NCT05359341
Drug: Sitagliptin 50 mg
RxNorm normalized name: SITagliptin 50 MG
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
Trial: NCT05359341
Drug: Empagliflozin 12.5 MG
RxNorm normalized name: empagliflozin 12.5 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.
Trial: NCT05359341
Drug: Sitagliptin 50 mg + Empagliflozin 12.5 MG
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)
Trial: NCT05359341
Drug: Empagliflozin 12.5 MG + Sitagliptin 50 mg
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)
Trial: NCT03010475
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration A total of three single doses.
Trial: NCT03010475
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration. Once daily.
Trial: NCT04376073
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body Weigh \<77 kg) po QD day1\~21, Anlotinib 12mg po QD day1\~14
Trial: NCT04376073
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg po QD day1\~14. Starting dose of anlotinib changed to 10mg from 2020-11-13.
Trial: NCT04450316
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5mg tab (low-dose) nightly
Trial: NCT02287610
Drug: RAYOS (delayed-release prednisone)
RxNorm normalized name: Rayos
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
Trial: NCT02111798
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
Trial: NCT03761537
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Trial: NCT00228332
Drug: Administration of zinkgluconaat or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00094900
Drug: IL-1 Trap
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04153734
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
Trial: NCT04153734
Drug: Cis Platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
Trial: NCT04153734
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
Trial: NCT04153734
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
Trial: NCT04153734
Drug: nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
Trial: NCT03341741
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin solution 2 x daily 1 Mega continuously
Trial: NCT00395551
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg intravitreal injection
Trial: NCT03679442
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
Trial: NCT01564056
Drug: CHEMOTHERAPY then HORMONOTHERAPY
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Trial: NCT00130312
Drug: Sulodexide
RxNorm normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg gelcap in the morning and evening
Trial: NCT03273257
Drug: Riociguat
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.
Trial: NCT00864019
Drug: Sertraline HCl 100 mg tablets, single dose
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
Trial: NCT03878693
Drug: Fomepizole
RxNorm normalized name: Fomepizole
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV 4-MP.
Trial: NCT03878693
Drug: APAP
RxNorm normalized name: APAP
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral APAP
Trial: NCT01915927
Drug: MSC-AFP
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00706498
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no